Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Psoriasis 2Lymphoma, Follicular 2Spondylitis, Ankylosing 1Periodic Fevers Syndrome 1Motor Activity 1Melanoma 1Crohn Disease 1Colorectal Neoplasms 1Arthritis, Rheumatoid 1

Interventions

Infliximab 5Certolizumab Pegol 5Adalimumab 3Nivolumab 2MEDI2070 2Educational Status 2CT-P13 2vedolizumab 1secukinumab 1golimumab 1cabozantinib 1Vitamin E 1Vaccines 1Ustekinumab 1Sutures 1Surveys and Questionnaires 1Surgical Instruments 1Standard of Care 1Specimen Handling 1Soybean Oil 1Saline Solution 1Ringer's Lactate 1Proctocolectomy, Restorative 1Practice Guidelines as Topic 1Pneumococcal Vaccines 1Platinum Compounds 1Photoplethysmography 1Phlebotomy 1Papillomavirus Vaccines 1Methoxsalen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Crohn Disease × secukinumab × Clear all
NCT00584740 2015-03-31

Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's Disease

Novartis

Phase 2 Terminated
59 enrolled 13 charts
Lymphoid

Crohn Disease, Lymphoma, Follicular, Motor Activity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡